Safety and immunogenicity of prepandemic H5N1 influenza vaccines: A systematic review of the literature

Abstract A systematic review was performed to assess the safety and immunogenicity of the prepandemic H5N1 influenza vaccines licensed so far. A bibliographic search according to the COSI protocol was carried out and 8 of 235 potentially relevant publications were selected. Quality assessment was de...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2010-06, Vol.28 (26), p.4328-4334
Main Authors: Prieto-Lara, Elisa, Llanos-Méndez, Aurora
Format: Article
Language:English
Subjects:
Adjuvants
Allergy and Immunology
Applied microbiology
Avian influenza
Biological and medical sciences
Check lists
Fundamental and applied biological sciences. Psychology
Humans
Immunogenicity
Influenza
Influenza A virus
Influenza A Virus, H5N1 Subtype - immunology
Influenza Vaccines - adverse effects
Influenza Vaccines - immunology
Influenza Vaccines - standards
Influenza, Human - epidemiology
Influenza, Human - prevention & control
Literature reviews
Microbiology
Miscellaneous
Mortality
Pandemics
Pharmaceutical industry
Prepandemic vaccines
Quality control
Reviews
Safety
Subtype H5N1
Systematic review
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract A systematic review was performed to assess the safety and immunogenicity of the prepandemic H5N1 influenza vaccines licensed so far. A bibliographic search according to the COSI protocol was carried out and 8 of 235 potentially relevant publications were selected. Quality assessment was defined with both CASP and Jadad checklists. Taken together, the results from the present systematic review suggest that the inactivated split-virion formulation that includes a low antigen dose (3.8 μg) and an oil-in-water emulsion-based adjuvant, represents the best option in the case of a pandemic, due to its antigen-sparing capacity and its favorable safety profile.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2010.03.068